JP2013523096A - インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用 - Google Patents

インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用 Download PDF

Info

Publication number
JP2013523096A
JP2013523096A JP2013501542A JP2013501542A JP2013523096A JP 2013523096 A JP2013523096 A JP 2013523096A JP 2013501542 A JP2013501542 A JP 2013501542A JP 2013501542 A JP2013501542 A JP 2013501542A JP 2013523096 A JP2013523096 A JP 2013523096A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
polynucleotide
vector
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013501542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523096A5 (enExample
Inventor
ティナ ガイナ，
マイケル レイシー，
マリオ スキアドポロス，
ヌータン ミトル，
Original Assignee
エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド filed Critical エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド
Publication of JP2013523096A publication Critical patent/JP2013523096A/ja
Publication of JP2013523096A5 publication Critical patent/JP2013523096A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013501542A 2010-03-26 2011-03-28 インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用 Pending JP2013523096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31823210P 2010-03-26 2010-03-26
US61/318,232 2010-03-26
PCT/US2011/030205 WO2011120045A1 (en) 2010-03-26 2011-03-28 Ectodomains of influenza matrix 2 protein, expression system, and uses thereof

Publications (2)

Publication Number Publication Date
JP2013523096A true JP2013523096A (ja) 2013-06-17
JP2013523096A5 JP2013523096A5 (enExample) 2013-07-25

Family

ID=44673677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501542A Pending JP2013523096A (ja) 2010-03-26 2011-03-28 インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用

Country Status (8)

Country Link
US (1) US20130115234A1 (enExample)
EP (1) EP2552490A4 (enExample)
JP (1) JP2013523096A (enExample)
CN (1) CN103118709A (enExample)
AU (1) AU2011230491A1 (enExample)
CA (1) CA2793772A1 (enExample)
SG (1) SG184155A1 (enExample)
WO (1) WO2011120045A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
US10286062B2 (en) 2013-07-09 2019-05-14 Texas Tech University System Universal influenza vaccine
CN105002149B (zh) * 2014-04-22 2018-04-06 中国科学院生物物理研究所 流感病毒rna聚合酶纯化或结晶的方法
CN105018441A (zh) * 2014-04-22 2015-11-04 中国科学院生物物理研究所 流感病毒rna聚合酶结晶的方法
WO2016131945A1 (en) * 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
WO2016176761A1 (en) * 2015-05-01 2016-11-10 Immunovaccine Technologies Inc., Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
CN110290805A (zh) * 2017-01-03 2019-09-27 埃默杰克斯疫苗控股有限公司 通用流感疫苗组合物
CN108373507A (zh) * 2018-01-18 2018-08-07 复旦大学 一种重组亚单位禽流感疫苗Sef4M2e
JP2025539418A (ja) * 2022-11-29 2025-12-05 ザ スクリプス リサーチ インスティテュート 新規ナノ粒子足場を含有するワクチン
WO2024196719A2 (en) * 2023-03-17 2024-09-26 Versatope Therapeutics, Inc. Membrane vesicles comprising multiple influenza antigens for vaccines
CN118530314B (zh) * 2024-06-06 2025-09-30 中国科学院武汉病毒研究所 广谱型流感疫苗抗原片段、重组益生菌及应用
CN119350508A (zh) * 2024-10-22 2025-01-24 成都纳微金生物技术有限公司 带广谱表位的三价流感纳米颗粒疫苗及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1616491A (zh) * 2004-09-29 2005-05-18 清华大学 具有防治流感作用的融合蛋白及其编码基因与应用
WO2008061939A1 (en) * 2006-11-20 2008-05-29 Paul-Ehrlich-Institut Bundesamt Für Sera Und Impfstoffe Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu
JP2008524261A (ja) * 2004-12-21 2008-07-10 バクシネート コーポレーション インフルエンザウイルスタンパク質の組成物およびその使用方法
WO2008129058A1 (en) * 2007-04-24 2008-10-30 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
WO2009026465A2 (en) * 2007-08-21 2009-02-26 Dynavax Technologies Corporation Composition and methods of making and using influenza proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
EP2253709B1 (en) * 2002-05-16 2018-04-11 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
US7354589B2 (en) * 2003-01-16 2008-04-08 The Wistar Institute Multiple antigenic agents and methods for using the same
CA2585104A1 (en) * 2004-12-06 2006-06-15 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
EP3058954B1 (en) * 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
CN101531719B (zh) * 2008-06-06 2011-09-14 江苏省农业科学院 一种禽流感基因工程多肽抗原
CN101643721B (zh) * 2009-08-17 2011-05-25 诺华生物科技（武汉）有限责任公司 广谱安全型动物用抗甲型流感病毒疫苗

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1616491A (zh) * 2004-09-29 2005-05-18 清华大学 具有防治流感作用的融合蛋白及其编码基因与应用
JP2008524261A (ja) * 2004-12-21 2008-07-10 バクシネート コーポレーション インフルエンザウイルスタンパク質の組成物およびその使用方法
WO2008061939A1 (en) * 2006-11-20 2008-05-29 Paul-Ehrlich-Institut Bundesamt Für Sera Und Impfstoffe Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu
WO2008129058A1 (en) * 2007-04-24 2008-10-30 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
WO2009026465A2 (en) * 2007-08-21 2009-02-26 Dynavax Technologies Corporation Composition and methods of making and using influenza proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6015015254; Ｄａｔａｂａｓｅ　ＵｎｉＰｒｏｔ　［ｏｎｌｉｎｅ］，　Ａｃｃｅｓｓｉｏｎ　Ｎｏ．　Ａ０ＲＴＩ９，　２００７-０１-０８　ｍｏｄｉｆｉｅｄ，　［ｒｅｔｒｉｅｖｅｄ　ｏｎ　２０１５-０４-０９］，　Ｍａｔ *
JPN6015015255; Ｄａｔａｂａｓｅ　ＵｎｉＰｒｏｔ　［ｏｎｌｉｎｅ］，　Ａｃｃｅｓｓｉｏｎ　Ｎｏ．　Ａ８ＢＵＦ５，　２００７-１１-１２　ｍｏｄｉｆｉｅｄ，　［ｒｅｔｒｉｅｖｅｄ　ｏｎ　２０１５-０４-０９］，　Ｍａｔ *
JPN6015015257; ＫＲＥＩＪＴＺ，　ＪＨ　ｅｔ　ａｌ．: '"ＭＶＡ-ｂａｓｅｄ　Ｈ５Ｎ１　ｖａｃｃｉｎｅ　ａｆｆｏｒｄｓ　ｃｒｏｓｓ-ｃｌａｄｅ　ｐｒｏｔｅｃｔｉｏｎ　ｉｎ　ｍｉｃｅ　ａｇａｉｎｓｔ　ｉｎｆｌｕｅｎｚａ　Ａ／Ｈ５Ｎ１　ｖｉｒｕｓｅｓ　ａｔ　ｌ' ＰＬｏＳ　Ｏｎｅ Ｖｏｌ．　４；　ｅ７７９０, 2009, ｐｐ．　１-８ *
JPN6015015259; ＫＲＥＩＪＴＺ，　ＪＨ　ｅｔ　ａｌ．: '"Ｐｒｅｃｌｉｎｉｃａｌ　ｅｖａｌｕａｔｉｏｎ　ｏｆ　ａ　ｍｏｄｉｆｉｅｄ　ｖａｃｃｉｎｉａ　ｖｉｒｕｓ　Ａｎｋａｒａ　（ＭＶＡ）-ｂａｓｅｄ　ｖａｃｃｉｎｅ　ａｇａｉｎｓｔ　ｉｎｆｌｕｅｎｚａ　Ａ／' Ｖａｃｃｉｎｅ Ｖｏｌ．　２７, 2009, ｐｐ．　６２９６-６２９９ *
JPN6015015260; ＬＯＨＲ，　Ｖ．　ｅｔ　ａｌ．: '"Ｎｅｗ　ａｖｉａｎ　ｓｕｓｐｅｎｓｉｏｎ　ｃｅｌｌ　ｌｉｎｅｓ　ｐｒｏｖｉｄｅ　ｐｒｏｄｕｃｔｉｏｎ　ｏｆ　ｉｎｆｌｕｅｎｚａ　ｖｉｒｕｓ　ａｎｄ　ＭＶＡ　ｉｎ　ｓｅｒｕｍ-ｆｒｅｅ　ｍｅｄｉａ：' Ｖａｃｃｉｎｅ Ｖｏｌ．　２７, 2009, ｐｐ．　４９７５-４９８２ *

Also Published As

Publication number Publication date
US20130115234A1 (en) 2013-05-09
WO2011120045A1 (en) 2011-09-29
CN103118709A (zh) 2013-05-22
SG184155A1 (en) 2012-10-30
EP2552490A1 (en) 2013-02-06
AU2011230491A1 (en) 2012-10-18
CA2793772A1 (en) 2011-09-29
EP2552490A4 (en) 2013-12-18

Similar Documents

Publication Publication Date Title
JP2013523096A (ja) インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用
US20210252129A1 (en) Zoonotic disease rna vaccines
US20110020391A1 (en) Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu
CN102257135B (zh) 流感疫苗的生产
EP2670430B1 (en) Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
US20110159031A1 (en) Vaccine to Influenza A Virus
JP2019510481A (ja) ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
US20120141525A1 (en) Universal influenza vaccine based on recombinant modified vaccine ankara virus (mva)
CN105143251B (zh) 流感核蛋白疫苗
CN111481663B (zh) 一种流感病毒活疫苗及其制备方法
CN110573614A (zh) 针对流感的免疫原性组合物
US20170151323A1 (en) Recombinant swine influenza virus and uses thereof
CN107841513B (zh) 基于M2e表位的广谱型流感疫苗
US20130243808A1 (en) Compositions and methods for vaccinating humans and animals against enveloped viruses
WO2010005474A1 (en) Recombinant modified vaccinia virus ankara (mva) expressing chlamydia polypeptide antigens
HK1183791A (en) Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
US20230174586A1 (en) Strain dis-derived recombinant vaccinia virus having novel influenza virus-derived hemagglutinin protein gene
HK1163177A (en) Production of influenza vaccines
HK1163177B (en) Production of influenza vaccines
NZ620275B2 (en) Recombinant swine influenza virus and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150416

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150924